Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EBT (2022 - 2026)

Zentalis Pharmaceuticals has reported EBT over the past 5 years, most recently at -$35.2 million for Q1 2026.

  • For Q1 2026, EBT rose 27.02% year-over-year to -$35.2 million; the TTM value through Mar 2026 reached -$123.6 million, up 44.87%, while the annual FY2025 figure was -$136.6 million, 17.55% up from the prior year.
  • EBT for Q1 2026 was -$35.2 million at Zentalis Pharmaceuticals, down from -$34.8 million in the prior quarter.
  • Over five years, EBT peaked at $10.2 million in Q1 2024 and troughed at -$99.5 million in Q2 2023.
  • A 5-year average of -$49.2 million and a median of -$48.5 million in 2022 define the central range for EBT.
  • Biggest five-year swings in EBT: soared 116.74% in 2024 and later tumbled 574.11% in 2025.
  • Year by year, EBT stood at -$48.5 million in 2022, then decreased by 25.87% to -$61.1 million in 2023, then rose by 21.94% to -$47.7 million in 2024, then grew by 27.06% to -$34.8 million in 2025, then dropped by 1.32% to -$35.2 million in 2026.
  • Business Quant data shows EBT for ZNTL at -$35.2 million in Q1 2026, -$34.8 million in Q4 2025, and -$26.7 million in Q3 2025.